|21st October 2020||Benjamin Wolin||21,615||Exercise of derivative||$0.00|
|21st October 2020||Benjamin Wolin||9,441||Payment by withholding||$27.04||$255,284.64|
|4th September 2020||Mark H Ravich||10,000||Other acquisition or disposition||$1.16||$11,600.00|
|4th September 2020||Mark H Ravich||16,000||Other acquisition or disposition||$1.16||$18,560.00|
|4th September 2020||Benjamin Wolin||9,259||Exercise of derivative||$0.00|
|4th September 2020||Mark H Ravich||9,000||Other acquisition or disposition||$1.16||$10,440.00|
|4th September 2020||Benjamin Wolin||3,993||Payment by withholding||$22.29||$89,003.97|
|4th September 2020||Mark H Ravich||25,000||Other acquisition or disposition||$1.22||$30,500.00|
|3rd September 2020||Mark H Ravich||173,905||Other acquisition or disposition||$1.21||$210,425.05|
|3rd September 2020||Mark H Ravich||11,000||Other acquisition or disposition||$1.21||$13,310.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.
Rockwell Medical, Inc. engages in targeting end-stage renal disease and chronic kidney disease. Its dialysis products include hemodialysis concentrates, citrapure, dri-sate, safety data sheets,ancillary products, and renal pure. The company was founded by Robert L. Chioini in January 1995.